These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

654 related articles for article (PubMed ID: 29588319)

  • 21. Oncolytic adeno-immunotherapy modulates the immune system enabling CAR T-cells to cure pancreatic tumors.
    Rosewell Shaw A; Porter CE; Yip T; Mah WC; McKenna MK; Dysthe M; Jung Y; Parihar R; Brenner MK; Suzuki M
    Commun Biol; 2021 Mar; 4(1):368. PubMed ID: 33742099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
    Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
    J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Systemic delivery of oncolytic herpes virus using CAR-T cells enhances targeting of antitumor immuno-virotherapy.
    Zhang Z; Yang N; Xu L; Lu H; Chen Y; Wang Z; Lu Q; Zhong K; Zhu Z; Wang G; Li H; Zheng M; Zhou L; Tong A
    Cancer Immunol Immunother; 2024 Jul; 73(9):173. PubMed ID: 38953982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.
    Baugh R; Khalique H; Page E; Lei-Rossmann J; Wan PK; Johanssen T; Ebner D; Ansorge O; Seymour LW
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38724464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.
    Watanabe N; McKenna MK; Rosewell Shaw A; Suzuki M
    Mol Ther; 2021 Feb; 29(2):505-520. PubMed ID: 33130314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic adenovirus targeting TGF-β enhances anti-tumor responses of mesothelin-targeted chimeric antigen receptor T cell therapy against breast cancer.
    Li Y; Xiao F; Zhang A; Zhang D; Nie W; Xu T; Han B; Seth P; Wang H; Yang Y; Wang L
    Cell Immunol; 2020 Feb; 348():104041. PubMed ID: 31983398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adenovirus-mediated specific tumor tagging facilitates CAR-T therapy against antigen-mismatched solid tumors.
    Tang X; Li Y; Ma J; Wang X; Zhao W; Hossain MA; Yang Y
    Cancer Lett; 2020 Sep; 487():1-9. PubMed ID: 32454143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.
    Scott EM; Duffy MR; Freedman JD; Fisher KD; Seymour LW
    Macromol Biosci; 2018 Jan; 18(1):. PubMed ID: 28902983
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine.
    Basnet S; Van der Heijden M; Quixabeira DCA; Jirovec E; Grönberg-Vähä-Koskela SAM; Clubb JHA; Kanerva A; Pakola S; Haybout L; Arias V; Hemminki O; Kudling T; Zafar S; Cervera-Carrascon V; Santos JM; Hemminki A
    Mol Ther; 2024 Sep; 32(9):3114-3127. PubMed ID: 38910324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites.
    Fu X; Rivera A; Tao L; Zhang X
    Oncotarget; 2015 Jan; 6(2):902-14. PubMed ID: 25460506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of virotherapy and T-cell therapy: arming oncolytic virus with T-cell engagers.
    Song XT
    Discov Med; 2013 Dec; 16(90):261-6. PubMed ID: 24333405
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release.
    Park JA; Santich BH; Xu H; Lum LG; Cheung NV
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986124
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer.
    Rosewell Shaw A; Porter CE; Watanabe N; Tanoue K; Sikora A; Gottschalk S; Brenner MK; Suzuki M
    Mol Ther; 2017 Nov; 25(11):2440-2451. PubMed ID: 28974431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of cryopreservation on chimeric antigen receptor T cell functions.
    Xu H; Cao W; Huang L; Xiao M; Cao Y; Zhao L; Wang N; Zhou J
    Cryobiology; 2018 Aug; 83():40-47. PubMed ID: 29908946
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
    Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
    Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human GUCY2C-Targeted Chimeric Antigen Receptor (CAR)-Expressing T Cells Eliminate Colorectal Cancer Metastases.
    Magee MS; Abraham TS; Baybutt TR; Flickinger JC; Ridge NA; Marszalowicz GP; Prajapati P; Hersperger AR; Waldman SA; Snook AE
    Cancer Immunol Res; 2018 May; 6(5):509-516. PubMed ID: 29615399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model.
    Soltantoyeh T; Akbari B; Shahosseini Z; Mirzaei HR; Hadjati J
    Front Immunol; 2024; 15():1362904. PubMed ID: 38855110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.